During his brief bid to become the Republican presidential nominee in 2023, Ramaswamy invoked his biotech credentials to ...

This week’s slate of Democratic winners have set their sights on expanding healthcare, removing RFK Jr. from HHS and pulling ...

Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these ...

The investor narrative around Eli Lilly is deeply rooted in obesity. The blockbuster GLP-1 medications Mounjaro and Zepbound are driving the large pharma’s gains in revenue, which rose 39% ...

After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more ...

Pharmaceuticals enable modern healthcare by helping to prevent, manage, and cure disease, but growing demand is increasing their impact on the environment. For oral drug delivery, medicines must be ...

The biopharma industry doesn’t have a technology problem, it has an implementation problem . Over the last few years, digital transformation has become one of the most widely di ...

The Keytruda biosimilars are coming. In October, the FDA accepted the first publicly announced application for a Keytruda copycat dubbed FYB206, which it could approve as early as the third quarter of ...

Anthropic is moving ahead with plans for an IPO that could become the largest in history. In an SEC filing ahead of its planned public offering, the company highlighted its work in the pharma arena as ...

America's leading pharma trade group is suing the Trump administration over drug pricing policies. On Oct. 7, the Pharmaceutical Research and Manufacturers of America, or PhRMA, challenged a new ...